Aronson, Stephen, Baelen, Bart Van, Kavanagh, Shane, Schwalen, Susanne

Background: Galantamine (hydrobromide), a reversible acetylcholinesterase inhibitor and allosteric nicotinic receptor modulator, slows cognitive and functional decline in mild to moderate dementia of the Alzheimer’s type. Although several drugs are indicated for mild to moderate Alzheimer’s disease (AD), no published study has separately analysed mild and moderate AD subgroups to assess the effect of dosage.; […]

Anderson, Craig, Teo, Koon, Gao, Peggy, Arima, Hisatomi, Dans, Antonio, Unger, Thomas, Commerford, Patrick, Dyal, Leanne, Schumacher, Helmut, Pogue, Janice, Paolasso, Ernesto, Holwerda, Nicolaas, Chazova, Irina, Binbrek, Azan, Young, James, Yusuf, Salim

Background: cardiovascular risk factors are associated with dementia and cognitive decline. We investigated the effects of renin-angiotensin system blockade on cognitive function in patients aged 55 years and older with established atherosclerotic cardiovascular disease or diabetes with end-organ damage in two clinical trials.; Methods: in the main study, ONTARGET, a double-blind, double-dummy, randomised controlled trial, […]

Allgaier, Antje-Kathrin, Kramer, Dietmar, Mergl, Roland, Fejtkova, Sabina, Hegerl, Ulrich

Objective: To assess and compare the validity of the German 15-item version and shortened versions of the Geriatric Depression Scale (GDS) for early detection of depression in nursing home residents with mild to moderate cognitive impairment (MMSE ≥ 15).; Methods: Data from 92 patients were analysed. The Structural Clinical Interview for DSM-IV (SCID) was used as […]

Aguiar, Paula, Monteiro, Larissa, Feres, Ana, Gomes, Irenio, Melo, Ailton

Objective: To determine the effects of rivastigmine patch associated with physical exercise versus rivastigmine patch alone in quality of life (QOL), cognition, activities of daily living (ADL) and functional mobility in Alzheimer’s disease (AD)subjects. Methods: A randomized, controlled, single-blinded trial was conducted in 40 patients with mild to moderate stages of AD. All patients were […]

Aarsland, Dag, Ballard, Clive, Walker, Zuzana, Bostrom, Fredrik, Alves, Guido, Kossakowski, Katja, Leroi, Iracema, Pozo-Rodriguez, Francisco, Minthon, Lennart, Londos, Elisabet

Background: Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are common forms of dementia that substantially affect quality of life. Currently, the only treatment licensed for PDD is rivastigmine, and there are no licensed treatments for DLB. We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine […]